Is a
Patent attributes
Current Assignee
Patent Jurisdiction
Patent Number
Date of Patent
January 10, 2012
Patent Application Number
12833417
Date Filed
July 9, 2010
Patent Citations Received
0
...
Patent Primary Examiner
Patent abstract
Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has the amino acid sequence shown in SEQ ID NO:4.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.